Ding Meng, Yang Siyu, Li Junli, Ma Lie, Xiong Cunyou, Zhang Jie
Department of Clinical Laboratory, The Second Hospital of Nanjing, Nanjing Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, 210003, China.
General Practice, The First Affiliated Hospital of Jilin University, Jilin, 130000, China.
BMC Endocr Disord. 2025 Apr 14;25(1):98. doi: 10.1186/s12902-025-01916-1.
The majority of diabetes cases fall into type 2 diabetes mellitus (T2DM), which is prone to chronic complications that have a long-term impact on patients. The aim of this study was to investigate the diagnostic potential of miR-214-3p in T2DM and its predictive value for chronic complications, providing a novel biomarker for the disease.
A total of 156 patients with T2DM and 80 non-T2DM individuals were included. Serum miR-214-3p levels were measured by real-time reverse transcription quantitative PCR (RT-qPCR). The correlation of miR-214-3p with hemoglobin A1c (HbA1c) and low-density lipoprotein cholesterol (LDL-C) was analyzed by Spearman's rank correlation. The clinical value of miR-214-3p in T2DM was evaluated using the receiver operating characteristic (ROC) curve and logistic regression analysis.
The serum levels of miR-214-3p were decreased in T2DM patients compared to non-T2DM individuals. A negative correlation was identified between miR-214-3p expression and the levels of HbA1c and LDL-C. miR-214-3p could effectively differentiate T2DM patients from non-T2DM individuals with the area under ROC curve (AUC) of 0.884. Patients with low miR-214-3p expression had a higher incidence of chronic complications. The AUC for miR-214-3p in differentiating between T2DM patients with and without complications was 0.832. Low expression of miR-214-3p was a risk factor linked to the development of chronic complications in patients with T2DM.
Serum miR-214-3p was downregulated in T2DM and could differentiate T2DM patients from non-T2DM individuals. miR-214-3p was a promising biomarker for predicting the chronic complications of T2DM.
大多数糖尿病病例属于2型糖尿病（T2DM），其易引发慢性并发症，对患者产生长期影响。本研究旨在探讨miR-214-3p在T2DM中的诊断潜力及其对慢性并发症的预测价值，为该疾病提供一种新的生物标志物。
共纳入156例T2DM患者和80例非T2DM个体。采用实时逆转录定量PCR（RT-qPCR）检测血清miR-214-3p水平。通过Spearman等级相关性分析miR-214-3p与糖化血红蛋白（HbA1c）和低密度脂蛋白胆固醇（LDL-C）的相关性。使用受试者工作特征（ROC）曲线和逻辑回归分析评估miR-214-3p在T2DM中的临床价值。
与非T2DM个体相比，T2DM患者血清miR-214-3p水平降低。miR-214-3p表达与HbA1c和LDL-C水平呈负相关。miR-214-3p能够有效区分T2DM患者和非T2DM个体，ROC曲线下面积（AUC）为0.884。miR-214-3p表达低的患者慢性并发症发生率更高。miR-214-3p区分有并发症和无并发症的T2DM患者的AUC为0.832。miR-214-3p低表达是T2DM患者发生慢性并发症的危险因素。
T2DM患者血清miR-214-3p下调，可区分T2DM患者和非T2DM个体。miR-214-3p是预测T2DM慢性并发症的有前景的生物标志物。
